For research use only. Not for therapeutic Use.
BT2（Cat No.:I017889） is a compound that acts as a dual inhibitor, targeting both BCKDC kinase (BDK) and Mcl-1. It exhibits an IC50 value of 3.19 μM against BDK, inhibiting its activity and causing dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). Additionally, BT2 acts as a potent and selective inhibitor of Mcl-1, with a Ki value of 59 μM. By targeting BDK and Mcl-1, BT2 has the potential to modulate important cellular processes and may be of interest for therapeutic applications.
| Catalog Number | I017889 |
| CAS Number | 34576-94-8 |
| Molecular Formula | C₉H₄Cl₂O₂S |
| Purity | ≥95% |
| Target | Bcl-2 Family |
| Storage | 2-8°C |
| IUPAC Name | 3,6-dichloro-1-benzothiophene-2-carboxylic acid |
| InChI | InChI=1S/C9H4Cl2O2S/c10-4-1-2-5-6(3-4)14-8(7(5)11)9(12)13/h1-3H,(H,12,13) |
| InChIKey | AAHPIJMQJAZYTM-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1Cl)SC(=C2Cl)C(=O)O |
| Reference | [1]. Tso SC, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. J Biol Chem. 2014 Jul 25;289(30):20583-93.<br>[2]. Friberg A, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56(1):15-30. |
